Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin J Filipski

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|September 4, 2007
Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-designScott D Larsen, Toni-Jo Poel, Kevin J Filipski, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2009
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycleJeffrey A Pfefferkorn, Jihong Lou, Martha L Minich, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
Novel and selective spiroindoline-based inhibitors of Sky kinaseNoel A Powell, Jeffrey T Kohrt, Kevin J Filipski, et al.
The Journal of Biological Chemistry|January 30, 2023
Structural studies identify angiotensin II receptor blocker-like compounds as branched-chain ketoacid dehydrogenase kinase inhibitorsShenping Liu, Bethany L Kormos, John D Knafels, et al.
ACS Medicinal Chemistry Letters|February 20, 2018
Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK InhibitorsMatthew F Sammons, Sujay V Kharade, Kevin J Filipski, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2013
Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemiaBenjamin D Stevens, John Litchfield, Jeffrey A Pfefferkorn, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2014
Identification of a novel conformationally constrained glucagon receptor antagonistEsther C Y Lee, Meihua Tu, Benjamin D Stevens, et al.
Bioorganic & Medicinal Chemistry|February 24, 2009
Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of actionChad A Van Huis, Agustin Casimiro-Garcia, Christopher F Bigge, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicityKevin J Filipski, Jianwei Bian, David C Ebner, et al.
ACS Medicinal Chemistry Letters|October 18, 2023
Design of Next-Generation DGAT2 Inhibitor PF-07202954 with Longer Predicted Half-LifeKevin J Filipski, David J Edmonds, Michelle R Garnsey, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|September 4, 2007
Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-designScott D Larsen, Toni-Jo Poel, Kevin J Filipski, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2009
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycleJeffrey A Pfefferkorn, Jihong Lou, Martha L Minich, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
Novel and selective spiroindoline-based inhibitors of Sky kinaseNoel A Powell, Jeffrey T Kohrt, Kevin J Filipski, et al.
The Journal of Biological Chemistry|January 30, 2023
Structural studies identify angiotensin II receptor blocker-like compounds as branched-chain ketoacid dehydrogenase kinase inhibitorsShenping Liu, Bethany L Kormos, John D Knafels, et al.
ACS Medicinal Chemistry Letters|February 20, 2018
Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK InhibitorsMatthew F Sammons, Sujay V Kharade, Kevin J Filipski, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2013
Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemiaBenjamin D Stevens, John Litchfield, Jeffrey A Pfefferkorn, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2014
Identification of a novel conformationally constrained glucagon receptor antagonistEsther C Y Lee, Meihua Tu, Benjamin D Stevens, et al.
Bioorganic & Medicinal Chemistry|February 24, 2009
Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of actionChad A Van Huis, Agustin Casimiro-Garcia, Christopher F Bigge, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicityKevin J Filipski, Jianwei Bian, David C Ebner, et al.
ACS Medicinal Chemistry Letters|October 18, 2023
Design of Next-Generation DGAT2 Inhibitor PF-07202954 with Longer Predicted Half-LifeKevin J Filipski, David J Edmonds, Michelle R Garnsey, et al.
Pageof 4